• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

    6.995 -12.705 (-64.49%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Capricor Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    Which stocks are moving on Monday? ↗
    Via Chartmill
    Monday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    These stocks that are showing activity before the opening bell on Monday. ↗
    Via Chartmill
    Capricor Therapeutics Inc (NASDAQ:CAPR) Q1 Results Show EPS Miss as Market Awaits August PDUFA Date ↗
    Via Chartmill
    Capricor Therapeutics Inc (NASDAQ:CAPR) Reports Q4 2025 Loss, Focus Remains on FDA Review for Deramiocel ↗
    Via Chartmill
    News headline image
    This Capricor Insider Sold 24,000 Shares Before the Drop. With a New Catalyst on the Way, Is It Time to Buy? ↗
    Focused on rare disease therapeutics, this biotech firm reported a notable insider sale amid a year of substantial stock gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    Curious about the stocks that are showing activity after the closing bell on Monday? ↗
    Via Chartmill
    News headline image
    Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy ↗
    Capricor Therapeutics (NASDAQ:CAPR) executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its... 
    Via MarketBeat
    News headline image
    Capricor (CAPR) Q1 2026 Earnings Transcript ↗
    Capricor (CAPR) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Capricor Therapeutics Q1 Earnings Call Highlights ↗
    Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story ↗
    Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval ↗
    On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval. 
    Via Stocktwits
    Topics Earnings
    News headline image
    CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval ↗
    The FDA has accepted Capricor’s resubmitted biologics license application, setting an Aug. 22 PDUFA decision date for Deramiocel in DMD. 
    Via Stocktwits
    Topics Earnings
    News headline image
    Capricor (CAPR) Q4 2025 Earnings Call Transcript ↗
    Capricor (CAPR) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy ↗
    For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024. 
    Via Stocktwits
    News headline image
    Capricor Therapeutics’ DMD Treatment Study Shows Improvement In Key Heart Function Measures ↗
    The update comes as the therapy’s regulatory application awaits a decision from the U.S. Food and Drug Administration later this year. 
    Via Stocktwits
    News headline image
    CAPR Stock Surged 17% Today — What’s Fueling The Rally? ↗
    The FDA has lifted a previous Complete Response Letter and resumed review of the company’s Biologics License Application for Deramiocel. 
    Via Stocktwits
    News headline image
    CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains ↗
    The FDA review of Deramiocel remains ongoing and could eventually lead to the assignment of a new PDUFA decision date. 
    Via Stocktwits
    News headline image
    Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? ↗
    Capricor is approaching a regulatory filing timeline and earnings, while Sarepta heads into results under legal and safety pressure. 
    Via Stocktwits
    News headline image
    Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
    Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Government
    News headline image
    CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On ↗
    Shares jumped over 14% on Thursday to their highest level and strongest session since December, when the company reported strong DMD trial results. 
    Via Stocktwits
    News headline image
    CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? ↗
    The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 
    Via Stocktwits
    News headline image
    Here's Why This Biotechnology Skyrocketed by 439% in December ↗
    A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an exciting new treatment. 
    Via The Motley Fool
    News headline image
    On Friday, there are stocks with unusual volume. Let's take a look. ↗
    The trading volume of these stocks is deviating from the norm in today's session. 
    Via Chartmill
    News headline image
    Let's take a look at the stocks that are in motion in today's session. ↗
    Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
    Via Chartmill
    News headline image
    Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire ↗
    DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder. 
    Via Stocktwits
    News headline image
    Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
    December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
    Via MarketMinute
    News headline image
    ‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win ↗
    Capricor’s positive HOPE-3 results prompted Shkreli to call his short thesis a “bad call” after the therapy showed statistically significant skeletal and cardiac benefits. 
    Via Stocktwits
    News headline image
    Why Did Capricor Therapeutics Stock Skyrocket Today? ↗
    The HOPE-3 study, involving 106 participants across 20 U.S. centres, delivered strong signals of benefit for muscle and heart function. 
    Via Stocktwits
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.